Nurix Therapeutics Ownership 2024 | Who Owns Nurix Therapeutics Now?
Institutional Ownership
118.18%
Insider Ownership
1.87%
Retail Ownership
-20.05%
Institutional Holders
173.00
Nurix Therapeutics Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| BLACKROCK INC. | 12.42% | 0.00% | 6,820,015 | 2,239,601 | 48.90% | 142,333,712 | Jun 30, 2024 |
| REDMILE GROUP, LLC | 8.06% | 5.58% | 4,423,616 | -59,400 | -1.32% | 92,320,866 | Jun 30, 2024 |
| DEEP TRACK CAPITAL, LP | 7.27% | 2.49% | 3,991,500 | 993,670 | 33.15% | 83,302,605 | Jun 30, 2024 |
| BAKER BROS. ADVISORS LP | 7.07% | 1.04% | 3,882,125 | - | - | 81,019,949 | Jun 30, 2024 |
| VANGUARD GROUP INC | 6.60% | 0.00% | 3,625,014 | 1,040,714 | 40.27% | 75,654,042 | Jun 30, 2024 |
| WELLINGTON MANAGEMENT GROUP LLP | 5.83% | 0.01% | 3,201,865 | 2,968,729 | 1273.39% | 66,822,922 | Jun 30, 2024 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 5.16% | 0.01% | 2,835,119 | 638,950 | 29.09% | 59,170,000 | Jun 30, 2024 |
| STATE STREET CORP | 4.93% | 0.00% | 2,708,533 | -20,803 | -0.76% | 56,527,084,000 | Jun 30, 2024 |
| ARK INVESTMENT MANAGEMENT LLC | 4.23% | 0.43% | 2,323,332 | -312,006 | -11.84% | 48,487,938 | Jun 30, 2024 |
| T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | 3.99% | 0.03% | 2,189,192 | 2,189,192 | 100.00% | 45,689,000 | Jun 30, 2024 |
| SOLEUS CAPITAL MANAGEMENT, L.P. | 3.74% | 3.78% | 2,055,916 | 940,916 | 84.39% | 42,906,967 | Jun 30, 2024 |
| MORGAN STANLEY | 3.62% | 0.00% | 1,989,700 | -541,099 | -21.38% | 41,525,039 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.41% | 0.00% | 1,321,734 | 221,399 | 20.12% | 27,589,926 | Jun 30, 2024 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 2.34% | 0.26% | 1,283,108 | 1,283,108 | 100.00% | 26,778,464 | Jun 30, 2024 |
| PICTET ASSET MANAGEMENT HOLDING SA | 2.14% | 0.03% | 1,173,518 | 446,577 | 61.43% | 24,491,321 | Jun 30, 2024 |
| CANDRIAM S.C.A. | 2.12% | 0.15% | 1,164,246 | 272,136 | 30.50% | 24,296,680 | Jun 30, 2024 |
| DEUTSCHE BANK AG\ | 1.91% | 0.01% | 1,048,394 | -450,974 | -30.08% | 21,879,983 | Jun 30, 2024 |
| NUVEEN ASSET MANAGEMENT, LLC | 1.79% | 0.01% | 981,167 | 562,344 | 134.27% | 20,476,956 | Jun 30, 2024 |
| AFFINITY ASSET ADVISORS, LLC | 1.66% | 2.19% | 912,000 | 101,747 | 12.56% | 19,033,440 | Jun 30, 2024 |
| WASATCH ADVISORS LP | 1.56% | 0.10% | 858,067 | -378,686 | -30.62% | 17,907,858 | Jun 30, 2024 |
Nurix Therapeutics's largest institutional shareholder is BLACKROCK INC., holding 12.42% of the company's total share outstanding, currently valued at $142.33M. The top 10 institutional shareholders own together 65.57% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| REDMILE GROUP, LLC | 8.06% | 5.58% | 4,423,616 | -59,400 | -1.32% | 92,320,866 | Jun 30, 2024 |
| SOLEUS CAPITAL MANAGEMENT, L.P. | 3.74% | 3.78% | 2,055,916 | 940,916 | 84.39% | 42,906,967 | Jun 30, 2024 |
| DEEP TRACK CAPITAL, LP | 7.27% | 2.49% | 3,991,500 | 993,670 | 33.15% | 83,302,605 | Jun 30, 2024 |
| AFFINITY ASSET ADVISORS, LLC | 1.66% | 2.19% | 912,000 | 101,747 | 12.56% | 19,033,440 | Jun 30, 2024 |
| OPALEYE MANAGEMENT INC. | 0.76% | 2.00% | 418,928 | 151,718 | 56.78% | 8,743,027 | Jun 30, 2024 |
| IKARIAN CAPITAL, LLC | 0.80% | 1.60% | 440,500 | 140,500 | 46.83% | 9,193,234 | Jun 30, 2024 |
| WESTHILL FINANCIAL ADVISORS, INC. | 0.52% | 1.43% | 283,333 | - | - | 5,913,160 | Jun 30, 2024 |
| PARKMAN HEALTHCARE PARTNERS LLC | 0.86% | 1.33% | 474,679 | 224,679 | 89.87% | 9,906,551 | Jun 30, 2024 |
| STEMPOINT CAPITAL LP | 0.37% | 1.25% | 203,273 | 203,273 | 100.00% | 4,242,308 | Jun 30, 2024 |
| BAKER BROS. ADVISORS LP | 7.07% | 1.04% | 3,882,125 | - | - | 81,019,949 | Jun 30, 2024 |
| VESTAL POINT CAPITAL, LP | 0.91% | 0.78% | 500,000 | 500,000 | 100.00% | 10,435,000 | Jun 30, 2024 |
| EAM INVESTORS, LLC | 0.32% | 0.59% | 174,077 | 174,077 | 100.00% | 3,632,987 | Jun 30, 2024 |
| ARK INVESTMENT MANAGEMENT LLC | 4.23% | 0.43% | 2,323,332 | -312,006 | -11.84% | 48,487,938 | Jun 30, 2024 |
| RHENMAN & PARTNERS ASSET MANAGEMENT AB | 0.32% | 0.35% | 174,393 | 174,393 | 100.00% | 3,639,582 | Jun 30, 2024 |
| PENNANT INVESTORS, LP | 0.10% | 0.31% | 56,800 | - | - | 1,185,416 | Jun 30, 2024 |
| INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 0.27% | 0.30% | 150,000 | 150,000 | 100.00% | 3,130,500 | Jun 30, 2024 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 2.34% | 0.26% | 1,283,108 | 1,283,108 | 100.00% | 26,778,464 | Jun 30, 2024 |
| SAMLYN CAPITAL, LLC | 1.06% | 0.20% | 583,490 | 583,490 | 100.00% | 12,177,436 | Jun 30, 2024 |
| RA CAPITAL MANAGEMENT, L.P. | 1.18% | 0.18% | 650,000 | 650,000 | 100.00% | 13,565,500 | Jun 30, 2024 |
| ALPHA DNA INVESTMENT MANAGEMENT LLC | 0.04% | 0.17% | 20,440 | 20,440 | 100.00% | 426,582 | Jun 30, 2024 |
The largest Nurix Therapeutics shareholder by % of total assets is REDMILE GROUP, LLC. The company owns 4.42M shares of Nurix Therapeutics (NRIX), representing 5.58% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| WELLINGTON MANAGEMENT GROUP LLP | 5.83% | 0.01% | 3,201,865 | 2,968,729 | 1273.39% | 66,822,922 | Jun 30, 2024 |
| BLACKROCK INC. | 12.42% | 0.00% | 6,820,015 | 2,239,601 | 48.90% | 142,333,712 | Jun 30, 2024 |
| T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | 3.99% | 0.03% | 2,189,192 | 2,189,192 | 100.00% | 45,689,000 | Jun 30, 2024 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 2.34% | 0.26% | 1,283,108 | 1,283,108 | 100.00% | 26,778,464 | Jun 30, 2024 |
| VANGUARD GROUP INC | 6.60% | 0.00% | 3,625,014 | 1,040,714 | 40.27% | 75,654,042 | Jun 30, 2024 |
| DEEP TRACK CAPITAL, LP | 7.27% | 2.49% | 3,991,500 | 993,670 | 33.15% | 83,302,605 | Jun 30, 2024 |
| SOLEUS CAPITAL MANAGEMENT, L.P. | 3.74% | 3.78% | 2,055,916 | 940,916 | 84.39% | 42,906,967 | Jun 30, 2024 |
| RA CAPITAL MANAGEMENT, L.P. | 1.18% | 0.18% | 650,000 | 650,000 | 100.00% | 13,565,500 | Jun 30, 2024 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 5.16% | 0.01% | 2,835,119 | 638,950 | 29.09% | 59,170,000 | Jun 30, 2024 |
| SAMLYN CAPITAL, LLC | 1.06% | 0.20% | 583,490 | 583,490 | 100.00% | 12,177,436 | Jun 30, 2024 |
| NUVEEN ASSET MANAGEMENT, LLC | 1.79% | 0.01% | 981,167 | 562,344 | 134.27% | 20,476,956 | Jun 30, 2024 |
| NORGES BANK | 0.92% | 0.00% | 507,536 | 507,536 | 100.00% | 10,592,276 | Jun 30, 2024 |
| VESTAL POINT CAPITAL, LP | 0.91% | 0.78% | 500,000 | 500,000 | 100.00% | 10,435,000 | Jun 30, 2024 |
| PICTET ASSET MANAGEMENT HOLDING SA | 2.14% | 0.03% | 1,173,518 | 446,577 | 61.43% | 24,491,321 | Jun 30, 2024 |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | 0.61% | 0.03% | 334,972 | 334,972 | 100.00% | 6,990,866 | Jun 30, 2024 |
| WOODLINE PARTNERS LP | 0.55% | 0.06% | 301,887 | 301,887 | 100.00% | 6,300,382 | Jun 30, 2024 |
| CANDRIAM S.C.A. | 2.12% | 0.15% | 1,164,246 | 272,136 | 30.50% | 24,296,680 | Jun 30, 2024 |
| MILLENNIUM MANAGEMENT LLC | 1.09% | 0.01% | 599,623 | 225,374 | 60.22% | 12,514,132 | Jun 30, 2024 |
| PARKMAN HEALTHCARE PARTNERS LLC | 0.86% | 1.33% | 474,679 | 224,679 | 89.87% | 9,906,551 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.41% | 0.00% | 1,321,734 | 221,399 | 20.12% | 27,589,926 | Jun 30, 2024 |
As of Jun 30 2024, Nurix Therapeutics's largest institutional buyer is WELLINGTON MANAGEMENT GROUP LLP. The company purchased 2.97M stocks of NRIX, valued at $66.82M.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC | - | - | - | -1,132,397 | -100.00% | - | Jun 30, 2024 |
| MORGAN STANLEY | 3.62% | 0.00% | 1,989,700 | -541,099 | -21.38% | 41,525,039 | Jun 30, 2024 |
| DEUTSCHE BANK AG\ | 1.91% | 0.01% | 1,048,394 | -450,974 | -30.08% | 21,879,983 | Jun 30, 2024 |
| WASATCH ADVISORS LP | 1.56% | 0.10% | 858,067 | -378,686 | -30.62% | 17,907,858 | Jun 30, 2024 |
| DIMENSIONAL FUND ADVISORS LP | 1.10% | 0.00% | 603,133 | -363,320 | -37.59% | 12,587,023 | Jun 30, 2024 |
| ARK INVESTMENT MANAGEMENT LLC | 4.23% | 0.43% | 2,323,332 | -312,006 | -11.84% | 48,487,938 | Jun 30, 2024 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 0.41% | 0.02% | 224,908 | -209,505 | -48.23% | 4,693,830 | Jun 30, 2024 |
| CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 0.11% | 0.01% | 62,298 | -174,806 | -73.73% | 1,300,159 | Jun 30, 2024 |
| TWO SIGMA INVESTMENTS, LP | 0.11% | 0.00% | 60,888 | -150,428 | -71.19% | 1,270,733 | Jun 30, 2024 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 0.11% | 0.00% | 60,084 | -127,659 | -68.00% | 1,254,000 | Jun 30, 2024 |
| RAFFERTY ASSET MANAGEMENT, LLC | 0.25% | 0.01% | 137,316 | -74,109 | -35.05% | 2,865,785 | Jun 30, 2024 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | 0.06% | 0.00% | 33,245 | -69,076 | -67.51% | 693,823 | Jun 30, 2024 |
| REDMILE GROUP, LLC | 8.06% | 5.58% | 4,423,616 | -59,400 | -1.32% | 92,320,866 | Jun 30, 2024 |
| AMERIPRISE FINANCIAL INC | 0.09% | 0.00% | 46,804 | -59,060 | -55.79% | 976,799 | Jun 30, 2024 |
| BESSEMER GROUP INC | 0.56% | 0.01% | 306,003 | -51,284 | -14.35% | 6,386,000 | Jun 30, 2024 |
| UBS GROUP AG | 0.22% | 0.00% | 118,563 | -50,379 | -29.82% | 2,474,410 | Jun 30, 2024 |
| RUSSELL INVESTMENTS GROUP, LTD. | 0.01% | 0.00% | 3,473 | -50,069 | -93.51% | 72,481 | Jun 30, 2024 |
| AMERICAN CENTURY COMPANIES INC | 0.02% | 0.00% | 10,124 | -49,942 | -83.15% | 211,288 | Jun 30, 2024 |
| ACADIAN ASSET MANAGEMENT LLC | 0.21% | 0.01% | 115,341 | -44,952 | -28.04% | 2,406,000 | Jun 30, 2024 |
| ENSIGN PEAK ADVISORS, INC | 0.06% | 0.00% | 35,644 | -44,263 | -55.39% | 743,890 | Jun 30, 2024 |
As of Jun 30 2024, Nurix Therapeutics's biggest institutional seller is BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC. The company sold -1.13M shares of NRIX, valued at -.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | 3.99% | 0.03% | 2,189,192 | 2,189,192 | 100.00% | 45,689,000 | Jun 30, 2024 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 2.34% | 0.26% | 1,283,108 | 1,283,108 | 100.00% | 26,778,464 | Jun 30, 2024 |
| RA CAPITAL MANAGEMENT, L.P. | 1.18% | 0.18% | 650,000 | 650,000 | 100.00% | 13,565,500 | Jun 30, 2024 |
| SAMLYN CAPITAL, LLC | 1.06% | 0.20% | 583,490 | 583,490 | 100.00% | 12,177,436 | Jun 30, 2024 |
| NORGES BANK | 0.92% | 0.00% | 507,536 | 507,536 | 100.00% | 10,592,276 | Jun 30, 2024 |
| VESTAL POINT CAPITAL, LP | 0.91% | 0.78% | 500,000 | 500,000 | 100.00% | 10,435,000 | Jun 30, 2024 |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | 0.61% | 0.03% | 334,972 | 334,972 | 100.00% | 6,990,866 | Jun 30, 2024 |
| WOODLINE PARTNERS LP | 0.55% | 0.06% | 301,887 | 301,887 | 100.00% | 6,300,382 | Jun 30, 2024 |
| STEMPOINT CAPITAL LP | 0.37% | 1.25% | 203,273 | 203,273 | 100.00% | 4,242,308 | Jun 30, 2024 |
| RHENMAN & PARTNERS ASSET MANAGEMENT AB | 0.32% | 0.35% | 174,393 | 174,393 | 100.00% | 3,639,582 | Jun 30, 2024 |
| EAM INVESTORS, LLC | 0.32% | 0.59% | 174,077 | 174,077 | 100.00% | 3,632,987 | Jun 30, 2024 |
| INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 0.27% | 0.30% | 150,000 | 150,000 | 100.00% | 3,130,500 | Jun 30, 2024 |
| UBS ASSET MANAGEMENT AMERICAS INC | 0.23% | 0.00% | 128,671 | 128,671 | 100.00% | 2,685,364 | Jun 30, 2024 |
| FARALLON CAPITAL MANAGEMENT LLC | 0.20% | 0.01% | 108,799 | 108,799 | 100.00% | 2,270,635 | Jun 30, 2024 |
| SWISS NATIONAL BANK | 0.18% | 0.00% | 99,200 | 99,200 | 100.00% | 2,070,304,000 | Jun 30, 2024 |
| QUBE RESEARCH & TECHNOLOGIES LTD | 0.17% | 0.00% | 95,424 | 95,424 | 100.00% | 1,991,499 | Jun 30, 2024 |
| FRED ALGER MANAGEMENT, LLC | 0.07% | 0.00% | 38,066 | 38,066 | 100.00% | 794,437 | Jun 30, 2024 |
| COREBRIDGE FINANCIAL, INC. | 0.06% | 0.00% | 32,557 | 32,557 | 100.00% | 679,465 | Jun 30, 2024 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 0.05% | 0.00% | 29,575 | 29,575 | 100.00% | 616,558 | Jun 30, 2024 |
| SQUAREPOINT OPS LLC | 0.05% | 0.00% | 28,784 | 28,784 | 100.00% | 600,722 | Jun 30, 2024 |
| STRS OHIO | 0.05% | 0.00% | 28,700 | 28,700 | 100.00% | 598,969,000 | Jun 30, 2024 |
| TD ASSET MANAGEMENT INC | 0.05% | 0.00% | 28,434 | 28,434 | 100.00% | 593,418 | Jun 30, 2024 |
| JANUS HENDERSON GROUP PLC | 0.05% | 0.00% | 26,200 | 26,200 | 100.00% | 546,532 | Jun 30, 2024 |
| WALLEYE CAPITAL LLC | 0.05% | 0.00% | 24,882 | 24,882 | 100.00% | 519,287 | Jun 30, 2024 |
| ALPHA DNA INVESTMENT MANAGEMENT LLC | 0.04% | 0.17% | 20,440 | 20,440 | 100.00% | 426,582 | Jun 30, 2024 |
| RAM INVESTMENT PARTNERS, LLC | 0.03% | 0.10% | 17,284 | 17,284 | 100.00% | 360,717 | Jun 30, 2024 |
| ARIZONA STATE RETIREMENT SYSTEM | 0.03% | 0.00% | 14,114 | 14,114 | 100.00% | 294,559 | Jun 30, 2024 |
| ALPINE GLOBAL MANAGEMENT, LLC | 0.02% | 0.05% | 12,681 | 12,681 | 100.00% | 264,652 | Jun 30, 2024 |
| GOTHAM ASSET MANAGEMENT, LLC | 0.02% | 0.00% | 11,872 | 11,872 | 100.00% | 247,769 | Jun 30, 2024 |
| TEACHER RETIREMENT SYSTEM OF TEXAS | 0.02% | 0.00% | 11,071 | 11,071 | 100.00% | 231,000 | Jun 30, 2024 |
| PEAK6 INVESTMENTS LLC | 0.02% | 0.00% | 10,000 | 10,000 | 100.00% | 208,700 | Jun 30, 2024 |
| DARK FOREST CAPITAL MANAGEMENT LP | 0.02% | 0.04% | 9,609 | 9,609 | 100.00% | 200,540 | Jun 30, 2024 |
| GREAT WEST LIFE ASSURANCE CO /CAN/ | 0.01% | 0.00% | 4,876 | 4,876 | 100.00% | 102,000 | Jun 30, 2024 |
| LAZARD ASSET MANAGEMENT LLC | 0.01% | 0.00% | 4,718 | 4,718 | 100.00% | 98,000 | Jun 30, 2024 |
| HARVEST FUND MANAGEMENT CO., LTD | 0.01% | 0.00% | 2,940 | 2,940 | 100.00% | 61,000 | Jun 30, 2024 |
| GROUP ONE TRADING, L.P. | 0.00% | 0.00% | 2,182 | 2,182 | 100.00% | 45,538,000 | Jun 30, 2024 |
| ADVISOR GROUP HOLDINGS, INC. | 0.00% | 0.00% | 1,283 | 1,283 | 100.00% | 26,776 | Jun 30, 2024 |
| MEEDER ASSET MANAGEMENT INC | 0.00% | 0.00% | 931 | 931 | 100.00% | 19,430 | Jun 30, 2024 |
| COPPELL ADVISORY SOLUTIONS LLC | 0.00% | 0.00% | 913 | 913 | 100.00% | 19,054 | Jun 30, 2024 |
| MARK SHEPTOFF FINANCIAL PLANNING, LLC | 0.00% | 0.00% | 400 | 400 | 100.00% | 8,348 | Jun 30, 2024 |
| MACROVIEW INVESTMENT MANAGEMENT LLC | 0.00% | 0.01% | 360 | 360 | 100.00% | 7,514 | Jun 30, 2024 |
| CWM, LLC | 0.00% | - | 142 | 142 | 100.00% | 3,000 | Jun 30, 2024 |
| SRS CAPITAL ADVISORS, INC. | 0.00% | 0.00% | 130 | 130 | 100.00% | 2,714 | Jun 30, 2024 |
| QUARRY LP | 0.00% | 0.00% | 65 | 65 | 100.00% | 1,357 | Jun 30, 2024 |
| LINDBROOK CAPITAL, LLC | - | - | 21 | 21 | 100.00% | 438 | Jun 30, 2024 |
| SMARTLEAF ASSET MANAGEMENT LLC | - | 0.00% | 17 | 17 | 100.00% | 352 | Jun 30, 2024 |
Nurix Therapeutics's largest new institutional shareholder by number of shares is T. ROWE PRICE INVESTMENT MANAGEMENT, INC., purchased 2.19M shares, valued at $45.69M, as of undefined.
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC | - | - | - | -1,132,397 | -100.00% | - | Jun 30, 2024 |
| AMUNDI | - | - | - | -43,755 | -100.00% | - | Jun 30, 2024 |
| CUBIST SYSTEMATIC STRATEGIES, LLC | - | - | - | -36,256 | -100.00% | - | Jun 30, 2024 |
| CORTON CAPITAL INC. | - | - | - | -27,375 | -100.00% | - | Jun 30, 2024 |
| BLACKSTONE INC. | - | - | - | -27,119 | -100.00% | - | Jun 30, 2024 |
| AMERICAN INTERNATIONAL GROUP, INC. | - | - | - | -23,460 | -100.00% | - | Jun 30, 2024 |
| J.W. COLE ADVISORS, INC. | - | - | - | -18,028 | -100.00% | - | Jun 30, 2024 |
| VERITION FUND MANAGEMENT LLC | - | - | - | -13,175 | -100.00% | - | Jun 30, 2024 |
| PRINCIPAL FINANCIAL GROUP INC | - | - | - | -12,953 | -100.00% | - | Jun 30, 2024 |
| 49 WEALTH MANAGEMENT, LLC | - | - | - | -12,503 | -100.00% | - | Jun 30, 2024 |
| CERITY PARTNERS LLC | - | - | - | -10,738 | -100.00% | - | Jun 30, 2024 |
| POINT72 ASSET MANAGEMENT, L.P. | - | - | - | -9,500 | -100.00% | - | Jun 30, 2024 |
| ENTRYPOINT CAPITAL, LLC | - | - | - | -8,335 | -100.00% | - | Jun 30, 2024 |
| TUCKER ASSET MANAGEMENT LLC | - | - | - | -4,135 | -100.00% | - | Jun 30, 2024 |
| METROPOLITAN LIFE INSURANCE CO/NY | - | - | - | -2,703 | -100.00% | - | Jun 30, 2024 |
| COMERICA BANK | - | - | - | -96 | -100.00% | - | Jun 30, 2024 |
| NELSON, VAN DENBURG & CAMPBELL WEALTH MANAGEMENT GROUP, LLC | - | - | - | -9 | -100.00% | - | Jun 30, 2024 |
Nurix Therapeutics's largest sold out institutional shareholder by shares sold is BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC, sold -1.13M shares, valued at -, as of undefined.
Nurix Therapeutics Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| Clough Global Equity Fund | 1.88% | 116,300 | - | - | Jan 31, 2024 |
| Endowment PMF Master Fund, L.P. | 0.60% | 1,203,002 | - | - | Mar 31, 2024 |
| Clough Global Opportunities Fund | 0.55% | 216,148 | - | - | Jan 31, 2024 |
| Clough Funds Trust | 0.47% | 19,300 | - | - | Jan 31, 2023 |
| CYPRESS CREEK PRIVATE STRATEGIES MASTER FUND L P | 0.40% | 788,816 | - | - | Mar 31, 2024 |
| Ark ETF Trust | 0.34% | 2,710,369 | -195,958 | -6.74% | Jan 31, 2024 |
| T. Rowe Price New Horizons Fund, Inc. | 0.23% | 1,140,710 | -181,673 | -13.74% | Mar 31, 2024 |
| WASATCH FUNDS TRUST | 0.13% | 1,172,986 | -877,295 | -42.79% | Mar 31, 2024 |
| PRUDENTIAL SECTOR FUNDS, INC. | 0.11% | 236,663 | - | - | Feb 29, 2024 |
| T. Rowe Price Health Sciences Fund, Inc. | 0.08% | 274,027 | - | - | Mar 31, 2024 |
| PRUDENTIAL JENNISON BLEND FUND, INC. | 0.07% | 41,789 | - | - | Feb 29, 2024 |
| VANGUARD VALLEY FORGE FUNDS | 0.06% | 29,820 | - | - | Mar 31, 2024 |
| PRUDENTIAL JENNISON SMALL CO FUND, INC. | 0.05% | 225,574 | - | - | Mar 28, 2024 |
| T. Rowe Price Small-Cap Value Fund, Inc. | 0.05% | 390,408 | - | - | Mar 31, 2024 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 0.05% | 177,232 | - | - | Mar 31, 2024 |
| T. Rowe Price Quantitative Management Funds, Inc. | 0.05% | 149,800 | - | - | Mar 31, 2024 |
| Vericimetry Funds | 0.03% | 2,750 | - | - | Mar 31, 2024 |
| Humankind Benefit Corp | 0.02% | 453 | - | - | Dec 31, 2023 |
| FIDELITY COMMONWEALTH TRUST | 0.02% | 52,523 | 837 | 1.62% | Feb 29, 2024 |
| QUANTITATIVE MASTER SERIES LLC | 0.01% | 84,632 | - | - | Mar 31, 2024 |
| DEUTSCHE DWS INVESTMENTS VIT FUNDS | 0.01% | 7,155 | - | - | Mar 31, 2024 |
| FORUM FUNDS II | 0.01% | 10,983 | 115 | 1.06% | Mar 31, 2024 |
| SCHWAB CAPITAL TRUST | 0.01% | 397,555 | 49,403 | 14.19% | Jan 31, 2024 |
| T. Rowe Price Equity Funds, Inc. | 0.01% | 93,042 | - | - | Mar 31, 2024 |
| UBS FUNDS | 0.01% | 31,550 | - | - | Mar 31, 2024 |
| ETFis Series Trust I | 0.01% | 9,179 | 168 | 1.86% | Jan 31, 2024 |
| TIAA SEPARATE ACCOUNT VA 1 | 0.01% | 1,379 | - | - | Mar 31, 2024 |
| T. Rowe Price Equity Series, Inc. | 0.01% | 10,001 | - | - | Mar 31, 2024 |
| Nushares ETF Trust | 0.01% | 37,014 | - | - | Jan 31, 2024 |
| VANGUARD INDEX FUNDS | 0.01% | 2,118,791 | -665,418 | -23.90% | Mar 31, 2024 |
| Fidelity Commonwealth Trust II | 0.00% | 30,648 | - | - | Aug 31, 2023 |
| TIAA-CREF LIFE FUNDS | 0.00% | 7,283 | -2,896 | -28.45% | Mar 31, 2024 |
| VARIABLE INSURANCE PRODUCTS FUND II | 0.00% | 26,381 | - | - | Mar 31, 2024 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 445,099 | 38,273 | 9.41% | Feb 29, 2024 |
| GOLDMAN SACHS VARIABLE INSURANCE TRUST | 0.00% | 8,147 | - | - | Mar 31, 2024 |
| Calvert Variable Products, Inc. | 0.00% | 4,621 | - | - | Mar 31, 2024 |
| FIDELITY COVINGTON TRUST | 0.00% | 31,583 | -365 | -1.14% | Mar 31, 2024 |
| CLEARWATER INVESTMENT TRUST | 0.00% | 16,022 | - | - | Mar 28, 2024 |
| T. Rowe Price Index Trust, Inc. | 0.00% | 37,260 | 151 | 0.41% | Mar 31, 2024 |
| MFS VARIABLE INSURANCE TRUST III | 0.00% | 22,891 | -7,071 | -23.60% | Mar 31, 2024 |
| VANGUARD HORIZON FUNDS | 0.00% | 28,686 | -102,682 | -78.16% | Mar 31, 2024 |
| ProFunds | 0.00% | 11,103 | 10,702 | 2668.83% | Mar 31, 2024 |
| NATIONWIDE VARIABLE INSURANCE TRUST | 0.00% | 123,015 | 32,066 | 35.26% | Mar 31, 2024 |
| ETF Series Solutions | 0.00% | 18,617 | 2,983 | 19.08% | Feb 29, 2024 |
| VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 25,730 | -2,230 | -7.98% | Mar 31, 2024 |
| HARTFORD SERIES FUND INC | 0.00% | 32,966 | - | - | Mar 31, 2024 |
| T. Rowe Price Spectrum Funds II, Inc. | 0.00% | 9,621 | - | - | Feb 29, 2024 |
| PUTNAM ASSET ALLOCATION FUNDS | 0.00% | 20,938 | -9,073 | -30.23% | Mar 31, 2024 |
| Dimensional ETF Trust | 0.00% | 280,203 | 62,949 | 28.97% | Jan 31, 2024 |
| Principal Exchange-Traded Funds | 0.00% | 7,517 | -617 | -7.59% | Mar 31, 2024 |
| JOHN HANCOCK INVESTMENT TRUST | 0.00% | 45,927 | - | - | Mar 31, 2024 |
| DFA INVESTMENT DIMENSIONS GROUP INC | 0.00% | 560,433 | -25,465 | -4.35% | Jan 31, 2024 |
| VANGUARD WORLD FUND | 0.00% | 131,712 | 672 | 0.51% | Feb 29, 2024 |
| North Square Investments Trust | 0.00% | 5,120 | - | - | Jan 31, 2024 |
| Global X Funds | 0.00% | 23,065 | - | - | Jan 31, 2024 |
| Direxion Shares ETF Trust | 0.00% | 77,567 | - | - | Jan 31, 2024 |
| Voya VARIABLE PORTFOLIOS INC | 0.00% | 15,985 | -22,471 | -58.43% | Mar 31, 2024 |
| STATE STREET VARIABLE INSURANCE SERIES FUNDS INC | 0.00% | 2,157 | -235 | -9.82% | Mar 31, 2024 |
| AMERICAN CENTURY ETF TRUST | 0.00% | 49,250 | 13,978 | 39.63% | Feb 29, 2024 |
| INVESCO EXCHANGE-TRADED FUND TRUST | 0.00% | 35,476 | 36 | 0.10% | Jan 31, 2024 |
| Managed Portfolio Series | 0.00% | 9,383 | - | - | Mar 31, 2024 |
| SCHWAB STRATEGIC TRUST | 0.00% | 231,151 | 7,829 | 3.51% | Feb 29, 2024 |
| MUTUAL FUND SERIES TRUST | 0.00% | 1,154,000 | - | - | Mar 31, 2024 |
| NORTHERN FUNDS | 0.00% | 38,467 | -7,344 | -16.03% | Mar 28, 2024 |
| STATE STREET INSTITUTIONAL INVESTMENT TRUST | 0.00% | 16,200 | 1,000 | 6.58% | Mar 31, 2024 |
| HARTFORD MUTUAL FUNDS II INC | 0.00% | 37,400 | - | - | Jan 31, 2024 |
| MASTER INVESTMENT PORTFOLIO | 0.00% | 20,080 | 8,316 | 70.69% | Mar 31, 2024 |
| FIDELITY SELECT PORTFOLIOS | 0.00% | 13,046 | -252,900 | -95.09% | Feb 29, 2024 |
| TIAA-CREF FUNDS | 0.00% | 587,432 | 84,162 | 16.72% | Jan 31, 2024 |
| Goldman Sachs ETF Trust | 0.00% | 18,321 | - | - | Feb 29, 2024 |
| SunAmerica Specialty Series | 0.00% | 92 | - | - | Apr 30, 2021 |
| SA FUNDS INVESTMENT TRUST | 0.00% | 2,828 | - | - | Mar 31, 2024 |
| VANGUARD VARIABLE INSURANCE FUNDS | 0.00% | 7,513 | - | - | Mar 31, 2024 |
| iSHARES TRUST | 0.00% | 2,149,682 | -121,642 | -5.36% | Mar 31, 2024 |
| GLENMEDE FUND INC | 0.00% | 1,056 | 1,056 | - | Jan 31, 2024 |
| FLEXSHARES TRUST | 0.00% | 8,771 | - | - | Jan 31, 2024 |
| EQ ADVISORS TRUST | 0.00% | 128,555 | -3,766 | -2.85% | Mar 31, 2024 |
| VANGUARD SCOTTSDALE FUNDS | 0.00% | 209,405 | 21,511 | 11.45% | Feb 29, 2024 |
| RYDEX SERIES FUNDS | 0.00% | 427 | - | - | Dec 31, 2023 |
| ALLIANZ VARIABLE INSURANCE PRODUCTS TRUST | 0.00% | 4,899 | - | - | Dec 31, 2023 |
| HC CAPITAL TRUST | 0.00% | 2,923 | - | - | Mar 31, 2024 |
| THRIVENT MUTUAL FUNDS | 0.00% | 7,901 | - | - | Mar 28, 2024 |
| RUSSELL INVESTMENT CO | 0.00% | 25,193 | 9,374 | 59.26% | Jan 31, 2024 |
| THRIVENT SERIES FUND INC | 0.00% | 8,362 | - | - | Mar 28, 2024 |
| VALIC Co I | 0.00% | 18,268 | -74 | -0.40% | Feb 29, 2024 |
| Guggenheim Active Allocation Fund | 0.00% | 373 | - | - | Feb 29, 2024 |
| ALLSPRING MASTER TRUST | 0.00% | 3,773 | - | - | Feb 29, 2024 |
| PENN SERIES FUNDS INC | 0.00% | 1,600 | - | - | Mar 28, 2024 |
| RUSSELL INVESTMENT FUNDS | 0.00% | 5,988 | 2,215 | 58.71% | Mar 31, 2024 |
| RYDEX DYNAMIC FUNDS | 0.00% | 212 | - | - | Dec 31, 2023 |
| COLUMBIA FUNDS VARIABLE INSURANCE TRUST | 0.00% | 29,418 | - | - | Mar 31, 2024 |
| GOLDMAN SACHS TRUST | 0.00% | 180,293 | 5,555 | 3.18% | Jan 31, 2024 |
| RBB FUND, INC. | 0.00% | 4,693 | - | - | Feb 29, 2024 |
| SPDR SERIES TRUST | 0.00% | 1,761,605 | 968,329 | 122.07% | Mar 31, 2024 |
| MAINSTAY FUNDS TRUST | 0.00% | 9,330 | 9,330 | - | Jan 31, 2024 |
| Brighthouse Funds Trust II | 0.00% | 38,659 | - | - | Mar 31, 2024 |
| PROSHARES TRUST | 0.00% | 10,603 | 1,382 | 14.99% | Feb 29, 2024 |
| SEASONS SERIES TRUST | 0.00% | 975 | -397 | -28.94% | Mar 31, 2024 |
| NATIONWIDE MUTUAL FUNDS | 0.00% | 5,215 | -33 | -0.63% | Jan 31, 2024 |
| MAINSTAY VP FUNDS TRUST | 0.00% | 4,913 | 4,913 | - | Mar 31, 2024 |
Nurix Therapeutics's largest mutual fund holder by % of total assets is "Clough Global Equity Fund", owning 116.30K shares, compromising 1.88% of its total assets.
Nurix Therapeutics Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 30 Jun, 24 | 173 | 23.57% |
| 31 Mar, 24 | 140 | 6.87% |
| 31 Dec, 23 | 131 | 0.77% |
| 30 Sep, 23 | 130 | 1.56% |
| 30 Jun, 23 | 128 | 3.23% |
| 31 Mar, 23 | 124 | 2.48% |
| 31 Dec, 22 | 121 | 3.42% |
| 30 Sep, 22 | 117 | 11.43% |
| 30 Jun, 22 | 105 | -9.48% |
| 31 Mar, 22 | 116 | -5.69% |
| 31 Dec, 21 | 123 | 8.85% |
| 30 Sep, 21 | 113 | 8.65% |
| 30 Jun, 21 | 104 | 4.00% |
| 31 Mar, 21 | 100 | 49.25% |
| 31 Dec, 20 | 67 | 3.08% |
| 30 Sep, 20 | 65 | - |
As of 30 Jun 24, 173 institutions are holding Nurix Therapeutics's shares, representing an increase of 23.57% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 30 Jun, 24 | 64,884,384 | 32.92% |
| 31 Mar, 24 | 48,814,624 | 6.47% |
| 31 Dec, 23 | 45,848,203 | 2.43% |
| 30 Sep, 23 | 44,760,099 | 2.77% |
| 30 Jun, 23 | 43,552,623 | 2.73% |
| 31 Mar, 23 | 42,393,398 | -0.67% |
| 31 Dec, 22 | 42,678,180 | -0.87% |
| 30 Sep, 22 | 43,051,932 | -4.32% |
| 30 Jun, 22 | 44,996,605 | 11.52% |
| 31 Mar, 22 | 40,347,184 | -0.12% |
| 31 Dec, 21 | 40,397,316 | 2.40% |
| 30 Sep, 21 | 39,449,433 | -0.20% |
| 30 Jun, 21 | 39,529,898 | -4.40% |
| 31 Mar, 21 | 41,348,953 | 24.81% |
| 31 Dec, 20 | 33,130,364 | 4.03% |
| 30 Sep, 20 | 31,845,915 | - |
Nurix Therapeutics (NRIX) has 64.88M shares outstanding as of 30 Jun 24, up 32.92% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 30 Jun, 24 | 118.18% | 1.49% |
| 31 Mar, 24 | 88.91% | 1.25% |
| 31 Dec, 23 | 84.29% | 1.24% |
| 30 Sep, 23 | 82.29% | 1.27% |
| 30 Jun, 23 | 80.61% | 1.31% |
| 31 Mar, 23 | 78.47% | 1.25% |
| 31 Dec, 22 | 79.12% | 1.10% |
| 30 Sep, 22 | 84.63% | 0.84% |
| 30 Jun, 22 | 100.22% | 1.23% |
| 31 Mar, 22 | 90.27% | 1.02% |
| 31 Dec, 21 | 94.18% | 1.19% |
| 30 Sep, 21 | 88.90% | 1.09% |
| 30 Jun, 21 | 90.24% | 0.79% |
| 31 Mar, 21 | 106.63% | 1.46% |
| 31 Dec, 20 | 85.60% | 1.26% |
| 30 Sep, 20 | 82.28% | - |
As of 30 Jun 24, Nurix Therapeutics is held by 118.18% institutional shareholders, representing a 1.49% growth compared to 31 Mar 24.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 111 | 58.57% |
| 31 Mar, 24 | 70 | 2.94% |
| 31 Dec, 23 | 68 | 23.64% |
| 30 Sep, 23 | 55 | -9.84% |
| 30 Jun, 23 | 61 | -1.61% |
| 31 Mar, 23 | 62 | -3.13% |
| 31 Dec, 22 | 64 | -5.88% |
| 30 Sep, 22 | 68 | 17.24% |
| 30 Jun, 22 | 58 | -10.77% |
| 31 Mar, 22 | 65 | - |
| 31 Dec, 21 | 65 | 14.04% |
| 30 Sep, 21 | 57 | -18.57% |
| 30 Jun, 21 | 70 | -7.89% |
| 31 Mar, 21 | 76 | 80.95% |
| 31 Dec, 20 | 42 | -35.38% |
| 30 Sep, 20 | 65 | - |
111 institutional shareholders have increased their position in NRIX stock as of 30 Jun 24 compared to 70 in the previous quarter (a 58.57% increase).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 45 | 4.65% |
| 31 Mar, 24 | 43 | 10.26% |
| 31 Dec, 23 | 39 | -23.53% |
| 30 Sep, 23 | 51 | 18.60% |
| 30 Jun, 23 | 43 | 16.22% |
| 31 Mar, 23 | 37 | 12.12% |
| 31 Dec, 22 | 33 | 32.00% |
| 30 Sep, 22 | 25 | -13.79% |
| 30 Jun, 22 | 29 | -6.45% |
| 31 Mar, 22 | 31 | -8.82% |
| 31 Dec, 21 | 34 | 6.25% |
| 30 Sep, 21 | 32 | 100.00% |
| 30 Jun, 21 | 16 | 60.00% |
| 31 Mar, 21 | 10 | -9.09% |
| 31 Dec, 20 | 11 | - |
| 30 Sep, 20 | - | - |
45 institutional shareholders have reduced their position in NRIX stock as of 30 Jun 24 compared to 43 in the previous quarter (a 4.65% increase).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 Jun, 24 | 173 | 23.57% | 64,884,384 | 32.92% | 118.18% | 1.49% | 111 | 58.57% | 45 | 4.65% |
| 31 Mar, 24 | 140 | 6.87% | 48,814,624 | 6.47% | 88.91% | 1.25% | 70 | 2.94% | 43 | 10.26% |
| 31 Dec, 23 | 131 | 0.77% | 45,848,203 | 2.43% | 84.29% | 1.24% | 68 | 23.64% | 39 | -23.53% |
| 30 Sep, 23 | 130 | 1.56% | 44,760,099 | 2.77% | 82.29% | 1.27% | 55 | -9.84% | 51 | 18.60% |
| 30 Jun, 23 | 128 | 3.23% | 43,552,623 | 2.73% | 80.61% | 1.31% | 61 | -1.61% | 43 | 16.22% |
| 31 Mar, 23 | 124 | 2.48% | 42,393,398 | -0.67% | 78.47% | 1.25% | 62 | -3.13% | 37 | 12.12% |
| 31 Dec, 22 | 121 | 3.42% | 42,678,180 | -0.87% | 79.12% | 1.10% | 64 | -5.88% | 33 | 32.00% |
| 30 Sep, 22 | 117 | 11.43% | 43,051,932 | -4.32% | 84.63% | 0.84% | 68 | 17.24% | 25 | -13.79% |
| 30 Jun, 22 | 105 | -9.48% | 44,996,605 | 11.52% | 100.22% | 1.23% | 58 | -10.77% | 29 | -6.45% |
| 31 Mar, 22 | 116 | -5.69% | 40,347,184 | -0.12% | 90.27% | 1.02% | 65 | - | 31 | -8.82% |
| 31 Dec, 21 | 123 | 8.85% | 40,397,316 | 2.40% | 94.18% | 1.19% | 65 | 14.04% | 34 | 6.25% |
| 30 Sep, 21 | 113 | 8.65% | 39,449,433 | -0.20% | 88.90% | 1.09% | 57 | -18.57% | 32 | 100.00% |
| 30 Jun, 21 | 104 | 4.00% | 39,529,898 | -4.40% | 90.24% | 0.79% | 70 | -7.89% | 16 | 60.00% |
| 31 Mar, 21 | 100 | 49.25% | 41,348,953 | 24.81% | 106.63% | 1.46% | 76 | 80.95% | 10 | -9.09% |
| 31 Dec, 20 | 67 | 3.08% | 33,130,364 | 4.03% | 85.60% | 1.26% | 42 | -35.38% | 11 | - |
| 30 Sep, 20 | 65 | - | 31,845,915 | - | 82.28% | - | 65 | - | - | - |
Nurix Therapeutics Insider Shareholders Trades
Open Market Insider Trades
Open Market Insider Buys
| Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
|---|
Insider Sells
All Insider Owners Trades
The last insider sell of Nurix Therapeutics's stock was made by van Houte Hans on Aug 01 2024, selling 3,377 shares at $21.43 per share (valued at $72.35K).
Nurix Therapeutics Insider Ownership Trends
All Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q3 2024 | 11 | 21 | 52.38% |
| Q2 2024 | 16 | 19 | 84.21% |
| Q1 2024 | 13 | 10 | 130.00% |
| Q4 2023 | 6 | 11 | 54.55% |
| Q3 2023 | 6 | 9 | 66.67% |
| Q2 2023 | 10 | 8 | 125.00% |
| Q1 2023 | 13 | 8 | 162.50% |
| Q4 2022 | 4 | 8 | 50.00% |
| Q3 2022 | 9 | 6 | 150.00% |
| Q2 2022 | 9 | 7 | 128.57% |
| Q1 2022 | 13 | 5 | 260.00% |
| Q4 2021 | 10 | 16 | 62.50% |
| Q3 2021 | 10 | 25 | 40.00% |
| Q2 2021 | 36 | 38 | 94.74% |
| Q1 2021 | 22 | 43 | 51.16% |
| Q4 2020 | 2 | 1 | 200.00% |
| Q3 2020 | 17 | 55 | 30.91% |
11 total buy trades, and 21 total sell trades (buy/sell ratio of 0.52%) were made by Nurix Therapeutics's insiders, as of Q3 2024.
Open Market Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q3 2024 | - | 9 | - |
| Q2 2024 | - | 9 | - |
| Q1 2024 | - | 4 | - |
| Q4 2023 | - | 5 | - |
| Q3 2023 | - | 3 | - |
| Q2 2023 | - | 4 | - |
| Q1 2023 | - | 4 | - |
| Q4 2022 | - | 4 | - |
| Q3 2022 | - | 4 | - |
| Q2 2022 | - | 4 | - |
| Q1 2022 | - | 2 | - |
| Q4 2021 | - | 8 | - |
| Q3 2021 | - | 14 | - |
| Q2 2021 | - | 18 | - |
| Q1 2021 | - | 26 | - |
| Q4 2020 | - | - | - |
| Q3 2020 | - | - | - |
As of Q3 2024, Insider owners conducted 0 open market buy trades and 9 open market sell trades of Nurix Therapeutics's stocks.
Nurix Therapeutics Peer Ownership
| Ticker | Company |
|---|---|
| PLRX | Pliant Therapeutics, Inc. |
| SANA | Sana Biotechnology, Inc. |
| KYMR | Kymera Therapeutics, Inc. |
| ARVN | Arvinas, Inc. |
| PRLD | Prelude Therapeutics Incorporated |
| FHTX | Foghorn Therapeutics Inc. |
| STOK | Stoke Therapeutics, Inc. |
| BDTX | Black Diamond Therapeutics, Inc. |
| GBIO | Generation Bio Co. |
| RLAY | Relay Therapeutics, Inc. |
| LYEL | Lyell Immunopharma, Inc. |
| CCCC | C4 Therapeutics, Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| NKTX | Nkarta, Inc. |
| STTK | Shattuck Labs, Inc. |
| ELYM | Eliem Therapeutics, Inc. |
NRIX Ownership FAQ
Who Owns Nurix Therapeutics?
Nurix Therapeutics is owned by institutional shareholders (118.18%), insiders (1.87%), and public (-20.05%). The largest institutional shareholder of Nurix Therapeutics is BLACKROCK INC. (12.42% of total shares) and the top mutual fund owner is Clough Global Equity Fund (1.88% of total shares).
Who are the major institutional shareholders of Nurix Therapeutics?
Nurix Therapeutics's major institutional shareholders are BLACKROCK INC., REDMILE GROUP, LLC, DEEP TRACK CAPITAL, LP, BAKER BROS. ADVISORS LP, and VANGUARD GROUP INC. The top five shareholders own together 41.42% of the company's share outstanding.
How many Nurix Therapeutics shareholders are there?
As of Jun 2024, there are 173 institutional shareholders of Nurix Therapeutics.
What percentage of Nurix Therapeutics is owned by BLACKROCK INC?
BLACKROCK INC owns 6.82M shares of Nurix Therapeutics, representing 12.42% of the company's total shares outstanding, valued at $142.33M (as of Jun 2024).
What percentage of Nurix Therapeutics is owned by REDMILE GROUP, LLC?
As of Jun 2024, REDMILE GROUP, LLC holds 4.42M shares of Nurix Therapeutics (NRIX), compromising 8.06% of the company, valued at $92.32M.
What percentage of Nurix Therapeutics is owned by DEEP TRACK CAPITAL, LP?
DEEP TRACK CAPITAL, LP is the third largest holder of Nurix Therapeutics. The company owns 3.99M of the company's shares outstanding (worth $83.3M).